Want to see RAPP full AI Analyst Report?
Top Page
Rapport Therapeutics, Inc.
(NASDAQ:RAPP)
Select Model
Select Model
Rating:53Neutral
Price Target:
$32.00
▼(-39.05% Downside)
Action:Reiterated
Date:08/05/26
The score is primarily constrained by weak financial performance—large operating losses and significant cash burn despite early revenue and strong gross margins. Technicals are a secondary positive with an improving trend and neutral momentum, while valuation remains challenged due to negative earnings and no dividend. Corporate events add a small governance-stability positive but do not materially change the risk profile.
Positive Factors
High Gross Margin
The emergence of $20.0M in trailing revenue alongside an approximately 96% gross margin indicates potentially attractive economics once products generate sales. If revenue scales, this margin profile could support reinvestment in development and improve long-term operating leverage.
Negative Factors
Deep Operating Losses
Rapport remains far from profitability, with substantial operating and research expenses overwhelming its nascent revenue base. Persistent losses reduce internal funding capacity and make future financial performance highly dependent on successful development milestones and continued access to capital.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
The emergence of $20.0M in trailing revenue alongside an approximately 96% gross margin indicates potentially attractive economics once products generate sales. If revenue scales, this margin profile could support reinvestment in development and improve long-term operating leverage.
Read all positive factors
Rapport Therapeutics, Inc. (RAPP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.54B
Dividend YieldN/A
Average Volume (3M)425.22K
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue GrowthN/A
EPS Growth-23.53%
CountryUS
Employees84
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.04
Shares Outstanding47,978,287
10 Day Avg. Volume618,796
30 Day Avg. Volume425,224
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue77.61
Enterprise Value/Gross Profit77.61
Enterprise Value/Ebitda-10.48
Forecast
1Y Price Target
$61.80Price Target Upside17.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$20.00M
Rapport Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorder...
How the Company Makes Money
As a clinical-stage biotechnology company, Rapport Therapeutics does not typically generate recurring revenue from marketed products and instead funds operations primarily through capital raising. Key sources of funds generally include (i) proceed...
Rapport Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 20.00M | -1.02M | 0.00 | 0.00 | -15.00K |
| EBITDA | -148.14M | -124.08M | -82.22M | -36.07M | -10.35M |
| Net Income | -137.16M | -111.48M | -78.31M | -34.79M | -10.65M |
Balance Sheet | |||||
| Total Assets | 458.98M | 512.43M | 314.93M | 155.42M | 31.60M |
| Cash, Cash Equivalents and Short-Term Investments | 436.08M | 490.54M | 305.28M | 147.48M | 31.16M |
| Total Debt | 10.11M | 11.48M | 1.48M | 2.15M | 10.44M |
| Total Liabilities | 36.06M | 27.78M | 9.51M | 181.06M | 12.10M |
| Stockholders Equity | 422.93M | 484.65M | 305.43M | -25.63M | 19.50M |
Cash Flow | |||||
| Free Cash Flow | -97.15M | -88.09M | -67.23M | -28.82M | -3.53M |
| Operating Cash Flow | -96.68M | -87.47M | -64.83M | -27.18M | -3.24M |
| Investing Cash Flow | -167.56M | -187.47M | -170.14M | -78.86M | -5.28M |
| Financing Cash Flow | 272.79M | 270.79M | 221.63M | 145.14M | 39.69M |
Rapport Therapeutics, Inc. Technical Analysis
Negative
52.50
Price Trends
43.11
Negative
40.97
Negative
35.81
Negative
Market Momentum
-3.62
Positive
22.62
Positive
11.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPP, the sentiment is Negative. The current price of 52.5 is above the 20-day moving average (MA) of 37.64, above the 50-day MA of 43.11, and above the 200-day MA of 35.81, indicating a bearish trend. The MACD of -3.62 indicates Positive momentum. The RSI at 22.62 is Positive, neither overbought nor oversold. The STOCH value of 11.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RAPP.
Rapport Therapeutics, Inc. Risk Analysis
Rapport Therapeutics, Inc. disclosed 87 risk factors in its most recent earnings report. Rapport Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rapport Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.49B | 4.28 | 30.03% | 7.39% | 18.17% | 693.83% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | $1.54B | -10.25 | -29.02% | ― | ― | -23.53% | |
46 Neutral | $3.33B | -25.85 | -18.55% | ― | ― | 16.63% | |
45 Neutral | $112.80M | -0.93 | -53.39% | 89.01% | 329.50% | -114.98% |
* General Sector Average
RAPP
Rapport Therapeutics, Inc.
31.15
4.71
17.81%
INVA
Innoviva
20.83
3.63
21.10%
ELVN
Enliven Therapeutics
42.39
22.28
110.79%
LENZ
LENZ Therapeutics
3.79
-43.15
-91.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.